Latest News
Cipla partners with Qilu Pharmaceutical for licensing and supply of Keytruda biosimilar in US
4 September 2026 - Invagen Pharmaceuticals Inc, a wholly owned subsidiary of India-based pharmaceutical company Cipla Limited (BSE:500087) (NSE:CIPLA), announced on Thursday that it has entered into a strategic partnership with China-based Qilu Pharm...
Cepheid's Xpert Hemorrhagic Fever Panel test granted WHO Emergency Use Listing to support DRC Ebola outbreak response
4 September 2026 - Molecular diagnostics company Cepheid, a Danaher (NYSE:DHR) company, announced on Thursday that it has received Emergency Use Listing (EUL) from the World Health Organization (WHO) for the Xpert Hemorrhagic Fever Panel test to supp...
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
4 September 2026 - Kali Therapeutics, a clinical-stage biotechnology company focused on new therapies for autoimmune and inflammatory diseases, announced on Thursday that the US Food and Drug Administration (FDA) has cleared the company's Invest...
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease
4 September 2026 - Thryv Therapeutics Inc, a clinical-stage biopharmaceutical company advancing selective SGK1 inhibitors, announced on Thursday that it has entered into an exclusive, worldwide, royalty-bearing patent and know-how licence agreement w...
Sensorion secures French approval for Phase I/II SENS-601 hearing-loss trial
3 September 2026 - Sensorion (Euronext Growth Paris:ALSEN), a clinical-stage biotechnology company that specialises in hearing loss therapies, said on Thursday that it has received authorisation from France's National Agency for Medicines and He...